What were the key takeaways from Arrowhead Pharmaceuticals's earnings call?

What does Arrowhead Pharmaceuticals do and what are its main business segments?

What guidance did Arrowhead Pharmaceuticals's management provide for the next earnings period?

Did Arrowhead Pharmaceuticals beat or miss consensus estimates last quarter?

What is Arrowhead Pharmaceuticals's gross profit margin?

What factors drove the changes in Arrowhead Pharmaceuticals's revenue and profit?

What is Arrowhead Pharmaceuticals's latest dividend and current dividend yield?

What is the revenue and EPS growth rate for Arrowhead Pharmaceuticals year over year?

- **FDA Breakthrough**: First siRNA therapy approved for FCS, addressing 6,500 high-risk patients with $60k/year pricing.
- **Pipeline Expansion**: 20+ clinical candidates, including Phase III zodasiran (HoFH) and novel dual-target ARO-DIMER-PA.
- **Strategic Wins**: $400M from Novartis/Sarepta, extending cash runway to 2028.
- **CNS Innovation**: ARO-MAPT achieves 75% tau knockdown in monkeys, targeting Alzheimer's with CNS delivery.

**【CEO Summary Section】**
- **FDA Approval Milestone**: REDEMPLO approved for FCS, the first siRNA therapy for this indication, targeting 6,500 U.S. patients with triglycerides 10-100x normal levels.
- **Pricing Strategy**: One-REDEMPLO model sets $60,000 annual price across all indications, emphasizing value for high-risk patients with triglycerides >880 mg/dL.
- **Pipeline Progress**: Zodasiran (HoFH) in Phase III, ARO-DIMER-PA (mixed hyperlipidemia) files Phase I/II, and ARO-MAPT (Alzheimer's) initiates CNS delivery trials.
- **Strategic Deals**: $200M upfront from Novartis for Parkinson's collaboration, $200M milestone from Sarepta for ARO-DM1.

**【CFO Financial Commentary】**
- **FY25 Financials**: Net loss $2M (vs. $599M prior), revenue $829M (84% from Sarepta). Operating expenses $731M (+21%), driven by R&D (+33%) and commercial prep.
- **Cash Position**: $919M as of Q4, with runway to 2028. Received $200M from Novartis and $200M Sarepta milestone post-period.
- **Revenue Drivers**: Sarepta ($697M), Sanofi ($130M), GSK ($2.6M). FY26 expects no material REDEMPLO impact, focusing on pipeline.

**【Q&A Key Highlights】**
- **Pancreatitis Studies**: SHASTA-3/4 (SHTG) powered for triglyceride reduction, SHASTA-5 designed for acute pancreatitis as primary endpoint.
- **Obesity Drugs**: ARO-INHBE Phase I data due Q1 2026, targeting 20M mixed hyperlipidemia patients.
- **CNS Innovation**: ARO-MAPT achieves 75% tau knockdown in monkeys, with CSF data expected Q2 2026.
- **Pediatric Plans**: Developing weight-based dosing for REDEMPLO to address childhood FCS.
- **Dimer Potential**: ARO-DIMER-PA aims to lower LDL and triglycerides with quarterly dosing, CVOT planned post-Phase I/II.

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

ARWR

ARWR fundamentals

You can ask Aime